SEATTLE--(BUSINESS WIRE)--ZymoGenetics, Inc. (NASDAQ:ZGEN) today announced that the company has begun treating patients in a Phase 2 safety and efficacy study of Interleukin 21 (IL-21) in previously untreated patients with metastatic melanoma. The study is being run by the National Cancer Institute of Canada Clinical Trials Group at Queen’s University located in Kingston, Ontario.
